This orally bioavailable compound selectively targets IKZF1 (Ikaros) and IKZF3 (Aiolos), causing tumor cell death upon their depletion from malignant B cells and T cell activation when depleted from the tumor microenvironment. This evidence concerns the gene IKZF3 and neoplasm.